C. Parker

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

A. Briggs, B. Woods, J. Eaton, 2017, Journal of medical economics.

Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales

S. Dewilde, W. Dunlop, B. Woods, 2014, Journal of medical economics.

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States

S. Sorensen, I. Proskorovsky, K. Deger, 2023, Advances in therapy.

Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma

B. Malcolm, S. Klijn, M. Treur, 2023, PharmacoEconomics - open.